Boehringer Ingelheim Animal Health — Cyborg Score 7/10
Solid
Animal Health / Veterinary Pharmaceuticals
Strategic Profile
The company is an integral part of a larger, family-owned global group founded in 1885 in Germany, also specializing in human pharmaceuticals and biopharmaceutical contract manufacturing. Boehringer Ingelheim acquired Merial, uniting the legacies, deep expertise, and broad product portfolios of the two into one of the world's leading animal health companies.
Cyborg Score Rationale
Strong market position as second-largest U.S. animal health player with established vaccine and therapeutic portfolios. Backed by a family-owned multinational with global resources. Limited visibility on recent financial performance and growth metrics constrains the score.
Top Insights
Operates across multiple high-value sectors including the pet industry, equine health, cattle farming, poultry production, and swine management.
U.S. business generated revenue of $440.4M, establishing significant market presence.
The company has filed 93 patents, signaling ongoing R&D investment.
FDA issued emergency use authorizations for animal drugs including three Boehringer Ingelheim products: Ivomec (ivermectin), NexGard (afoxolaner), and NexGard Combo, aimed at preventing New World screwworm parasitic threat.
Named Competitors
Dechra — Veterinary pharmaceuticals and animal health
Ceva — Animal health vaccines and diagnostics
Heska — Veterinary diagnostic and software solutions
Recent Developments
(May 2026) Official company presence confirmed with active operations across U.S. states and Puerto Rico
(2016) Bayer AG acquired BIVI's Cydectin bovine & ovine endectocide products, indicating product licensing activity in the market
Open the full interactive Boehringer Ingelheim Animal Health report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.